QuidelOrtho Corporation QDEL released preliminary Q3 revenue of $738 million to $744 million, primarily driven by higher respiratory product sales, particularly SARS and flu.
The company says earlier-than-expected demand for respiratory products in core markets drives strong preliminary performance.
The company sees non-respiratory product revenue of $557 million-$560 million and respiratory product revenue of $181 million-$184 million.
William Blair says respiratory product revenue is well above their estimate of $101 million.
The upside here comes as little surprise given management's intra-quarter bullish tone on respiratory (COVID) testing demand from retail and point-of-care settings; however, the magnitude of the beat is surprising.
On the non-respiratory side, sales grew approximately 2% Y/Y (reported) to $559 million at the midpoint, missing William Blair's estimate and consensus by just over $10 million.
While commentary in the press release noted that this met the team's internal expectations—including for China— the analyst writes that investors will be focused on drivers of the non-respiratory segment in the quarter as this is more likely to drive long-term value in the stock.
Due to the ongoing uncertainty surrounding the core profitability outlook, China-related risks, and the Savanna pipeline, sentiment may continue to display a degree of mixed sentiment.
However, William Blair writes that the current share valuation presents an entry opportunity.
This valuation doesn't adequately account for the growth potential, free cash flow, and a notably diversified business portfolio compared to the historical norm.
William Blair reaffirms an Outperform for the stock.
Price Action: QDEL shares are down 4.69% at $65.96 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.